This statistic depicts the percentage of executives that selected current and projected areas of most impact to real-world evidence ( RWE ) in clinical trials , as of 2018 . According to the source , 60 percent of executives said that a better understanding of subpopulations and heterogeneity of treatment effects would be most impactful to current real-world evidence .
